Truist reiterates Salesforce stock Buy rating after developer event

Truist reiterated a Buy rating and $280 price target on Salesforce, implying significant upside from the current $181.32 share price. The firm said customer feedback from TDX was constructive: LLM-based agentic coding is not displacing Salesforce, Agentforce pricing remains refinable, and Salesforce Flow is well received. Truist sees pricing tweaks and improved agent scalability helping reduce friction and support adoption in 2026.

Analysis

The market is still treating this as a product story, but the more important read-through is monetization friction. If Agentforce pricing is too rich relative to perceived labor replacement value, adoption can lag even when technical interest is high; that creates a classic “usage first, wallet later” path where bookings only inflect after packaging is simplified. In that setup, the near-term winner is CRM’s installed base durability, but the bigger second-order beneficiary is any vendor that can position itself as the cheaper orchestration layer around Salesforce rather than a direct replacement.

The competitive threat is less from large-model coding tools and more from adjacent workflow platforms that can absorb lightweight automation demand before it becomes a CRM expansion event. That makes PATH relevant: if buyers are still experimenting with AI agents but balking at enterprise-wide pricing, automation budgets may drift toward narrower, task-specific deployments instead of broad CRM add-ons. Over the next 2-3 quarters, the key variable is whether Salesforce can convert positive product reception into higher seat density and usage-based attach without increasing discounting.

The contrarian angle is that consensus may be too anchored on a 2026 acceleration narrative, which leaves the stock vulnerable if 2025 remains a digestion year. At the current setup, upside is more likely to come from multiple expansion on improving sentiment than from immediate operating surprises; that makes CRM less attractive as a straight long into a strong tape unless there is evidence of faster-than-expected agent monetization. The risk case is simple: if pricing stays sticky and implementation ROI takes longer than expected, customer enthusiasm can coexist with flat revenue contribution for several quarters.

For timing, the catalyst window is next 1-2 quarters of commentary on pricing, attach rates, and agent usage metrics; failure to improve those would force a reset in the 2026 bull case. If management signals packaging changes or materially lower buyer friction, the move could re-rate quickly because expectations are still not fully embedded in near-term numbers.

Key Decisions for Investors

• Long CRM on a 3-6 month horizon only on confirmation of pricing/package revisions; target a re-rate toward the sell-side upside case, but keep a tight stop if agent monetization commentary remains vague.
• Pair trade: long CRM / short PATH for 1-2 quarters if you believe enterprise automation budgets consolidate into the incumbent platform rather than broadening to stand-alone RPA spend; risk is PATH wins share on lower-cost deployment.
• Buy CRM call spreads 4-6 months out to express upside from multiple expansion while capping premium if 2025 remains a digestion period; best entry is after any post-conference drift rather than chasing strength.
• If you want a cleaner contrarian expression, short a basket of high-multiple workflow/automation names against CRM on the thesis that budget cycles favor integrated platforms over point solutions once AI experimentation normalizes.